U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06922240) titled 'Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)' on March 23.
Brief Summary: Riociguat and balloon pulmonary angioplasty (BPA) are established standard-of-care interventions for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) with comparable evidence levels. However, the optimal combined treatment strategy remains unclear. Specifically, there is no consensus on whether riociguat should be continued long-term after achieving hemodynamic stability with BPA. Additionally, the long-term effects of riociguat discontinuation on right ventricular (RV) structure and function remain poorly characterized, p...